Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
A significant proportion of heart failure patients develop skeletal muscle wasting and cardiac cachexia, which is associated with a very poor prognosis. Recently, myostatin, a cytokine from the transforming growth factor-β (TGF-β) family and a known strong inhibitor of skeletal muscle growth, has been identified as a direct mediator of skeletal muscle atrophy in mice with heart failure. Myostatin is mainly expressed in skeletal muscle, although basal expression is also detectable in heart and adipose tissue. During pathological loading of the heart, the myocardium produces and secretes myostatin into the circulation where it inhibits skeletal muscle growth. Thus, genetic elimination of myostatin from the heart reduces skeletal muscle atrophy in mice with heart failure, whereas transgenic overexpression of myostatin in the heart is capable of inducing muscle wasting. In addition to its endocrine action on skeletal muscle, cardiac myostatin production also modestly inhibits cardiomyocyte growth under certain circumstances, as well as induces cardiac fibrosis and alterations in ventricular function. Interestingly, heart failure patients show elevated myostatin levels in their serum. To therapeutically influence skeletal muscle wasting, direct inhibition of myostatin was shown to positively impact skeletal muscle mass in heart failure, suggesting a promising strategy for the treatment of cardiac cachexia in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582 · cited 1×
“The serum concentrations of proinflammatory cytokines like TNF- , IL-6, and IL-1 are known to be high in patients with cardiac cachexia (8, 45, 82).”
BackgroundDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“Mutations in the myostatin gene have been shown to be responsible for the double muscling phenotype in cattle (54).”
BackgroundRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 1×
“For example, inhibition of myostatin by antibody (clone JA-16 or PF-354) has been shown to ameliorate muscle pathology and to increase strength, especially in younger mice with different forms of muscular dystrophy (16, 59, 61, 86).”
BackgroundREGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819 · cited 1×
“Among the TGF- family of genes, myostatin forms a distinct subgroup together with gdf-11, with which it shares 90% amino acid identity in the COOH-terminal domain (41).”
BackgroundPlasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure
Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., Niebauer, J., Hooper, J., Volk, H.-D., Coats, A. J. S., et al. (2000) · Circulation · doi:10.1161/01.cir.102.25.3060 · Cited by 810
Anker, S. D., Chua, T. P., Ponikowski, P., Harrington, D., Swan, J. W., Kox, W. J., Poole-Wilson, P. A., & Coats, A. J. S. (1997) · Circulation · doi:10.1161/01.cir.96.2.526 · Cited by 800
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Myostatin negatively regulates satellite cell activation and self-renewal
McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., & Kambadur, R. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207056 · Cited by 784 · cited 1×
“Which genes are influenced by myostatin binding to its target cells? It was reported that myostatin inhibits the proliferation of myoblasts and satellite cells by influencing the expression of genes participating in cell cycle regulation like, for example, p21 (upregulation by myostatin), CDK2, or Wnt4 (both repressed…”
BackgroundInflammatory mediators in chronic heart failure: an overview
Anker, S. D., & von Haehling, S. (2004) · Heart · doi:10.1136/hrt.2002.007005 · Cited by 627 · cited 1×
“It has also been demonstrated that TNFimpairs endothelial function with a decreased blood and nutrient supply to skeletal muscle, thus reducing exercise endurance (13).”
BackgroundGonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14938 · Cited by 571 · cited 1×
“Increased levels of muscle myostatin and/or serum myostatin have been reported in human patients with human immunodeficiency syndrome, chronic obstructive pulmonary disease, and heart failure, opening up a whole range of different possible applications for ActRIIB inhibition (24, 28, 30, 62).”
BackgroundSmad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517 · cited 8×
“mTOR is capable of regulating protein synthesis and cell size, but only around 40% of the hypertrophic effects of blocking myostatin can be reversed by anti-mTOR agents (70, 92).”
BackgroundInfluentialSuppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505 · cited 1×
“Besides the increased muscularity, the myostatin knockout mice also have reduced body fat with increasing age and are also protected against obesity triggered in genetic models (55).”
BackgroundA phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481
Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways
Lee, S.-J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000789 · Cited by 316
Regulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 2×
“Moreover, heterozygous activin-A knockout mice show increased skeletal muscle weights while overexpression of activin-A induces muscle atrophy (26, 42).”
BackgroundGilson, H., Schakman, O., Kalista, S., Lause, P., Tsuchida, K., & Thissen, J.-P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2009 · Cited by 248 · cited 3×
“Moreover, heterozygous activin-A knockout mice show increased skeletal muscle weights while overexpression of activin-A induces muscle atrophy (26, 42).”
BackgroundGenetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238 · cited 9×
“Serum levels of myostatin were increased by three- to fourfold in these transgenic mice compared with nontransgenic littermates (similar to what we observed during pressure overload) and indeed show significantly reduced skeletal muscle weights (minus 13 to 30%, again similar to the reduced muscle weights in wild-type…”
BackgroundInfluentialTranscriptional effects of chronic Akt activation in the heart
Cook, S. A., Matsui, T., Li, L., & Rosenzweig, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201462200 · Cited by 199
Cellular Markers of Muscle Atrophy in Chronic Obstructive Pulmonary Disease
Plant, P. J., Brooks, D., Faughnan, M., Bayley, T., Bain, J., Singer, L., Correa, J., Pearce, D., Binnie, M., & Batt, J. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0382oc · Cited by 190 · cited 1×
“Increased levels of muscle myostatin and/or serum myostatin have been reported in human patients with human immunodeficiency syndrome, chronic obstructive pulmonary disease, and heart failure, opening up a whole range of different possible applications for ActRIIB inhibition (24, 28, 30, 62).”
BackgroundAllen, D. L., Cleary, A. S., Speaker, K. J., Lindsay, S. F., Uyenishi, J., Reed, J. M., Madden, M. C., & Mehan, R. S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00798.2007 · Cited by 183
Myostatin activation in patients with advanced heart failure and after mechanical unloading
George, I., Bish, L. T., Kamalakkannan, G., Petrilli, C. M., Oz, M. C., Naka, Y., Lee Sweeney, H., & Maybaum, S. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq039 · Cited by 136
Myostatin Up-Regulation Is Associated with the Skeletal Muscle Response to Hypoxic Stimuli
Hayot, M., Rodriguez, J., Vernus, B., Carnac, G., Jean, E., Allen, D., Goret, L., Obert, P., Candau, R., & Bonnieu, A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.09.008 · Cited by 98 · cited 1×
“Increased levels of muscle myostatin and/or serum myostatin have been reported in human patients with human immunodeficiency syndrome, chronic obstructive pulmonary disease, and heart failure, opening up a whole range of different possible applications for ActRIIB inhibition (24, 28, 30, 62).”
Background
Cited by
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
Muscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421
Satellite cells in human skeletal muscle plasticity
Snijders, T., Nederveen, J. P., McKay, B. R., Joanisse, S., Verdijk, L. B., van Loon, L. J. C., & Parise, G. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00283 · Cited by 359
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Curcio, F., Testa, G., Liguori, I., Papillo, M., Flocco, V., Panicara, V., Galizia, G., Della-Morte, D., Gargiulo, G., Cacciatore, F., et al. (2020) · Nutrients · doi:10.3390/nu12010211 · Cited by 258
Metadata
- Authors
- Breitbart, A., Auger-Messier, M., Molkentin, J. D., & Heineke, J.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2011-06
- Volume
- 300
- Issue
- 6
- Pages
- H1973-H1982
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2168867523
- Cited by
- 131
- References
- 25
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.